Skip to main content
    T

    Tscan Therapeutics Inc (TCRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.15
    -0.02 (-9.65%)

    Market Cap: $10.89M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Tscan Therapeutics Inc (TCRX) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Tscan Therapeutics (TCRX) is expected to report earnings on Mar 2, 2027. In the quarter ended Sep 30, 2026, Tscan Therapeutics reported EPS of -$0.25, below the -$0.18 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(13/23)
    Avg Surprise
    +2.04%

    Upcoming Estimates

    Reports Mar 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.17
    Range-$0.21 - -$0.09
    6 analysts
    Revenue Consensus
    $606.90K
    RangeN/A
    6 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.19
    Range-$0.26 - -$0.11
    2 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.24+21.3%
    60d ago-$0.24+21.3%
    30d ago-$0.24+21.3%
    7d ago-$0.25+26.0%
    Current-$0.19
    Revenue Consensus
    $433.33K
    RangeN/A
    3 analysts

    Next Report

    TCRX has an expected report date of Mar 2, 2027.

    Earnings History

    Of the 23 quarters below that had an estimate, TCRX beat 13, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $586000, down 76.7% from $2.51M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.25-$0.18-$0.23 - -$0.08-38.89%MissN/A42 up, 2 downNov 12, 2026$586000
    Jun 30, 2026-$0.23-$0.29N/A+20.69%BeatN/A40 up, 4 downAug 12, 2026$1.05M
    Mar 31, 2026-$0.22-$0.16-$0.18 - -$0.13-37.50%MissN/A43 up, 0 downMay 6, 2026$982000
    Dec 31, 2025-$0.18-$0.27-$0.42 - -$0.19+32.61%BeatN/A51 up, 2 downMar 4, 2026$2.57M
    Sep 30, 2025-$0.28-$0.33-$0.57 - -$0.24+15.15%BeatN/A61 up, 1 downNov 12, 2025$2.51M
    Jun 30, 2025-$0.28-$0.32-$0.58 - -$0.22+12.50%BeatN/A62 up, 1 downAug 12, 2025$3.08M
    Mar 31, 2025-$0.26-$0.28-$0.32 - -$0.21+7.14%BeatN/A51 up, 0 downMay 6, 2025$2.17M
    Dec 31, 2024-$0.30-$0.29-$0.30 - -$0.24-3.45%MissN/A52 up, 0 downMar 5, 2025$665000
    Sep 30, 2024-$0.25-$0.29-$0.34 - -$0.24+13.79%BeatN/A70 up, 0 downNov 12, 2024$1.05M
    Jun 30, 2024-$0.28-$0.28-$0.35 - -$0.230.00%In lineN/A70 up, 0 downAug 12, 2024$536000
    Mar 31, 2024-$0.32-$0.24-$0.27 - -$0.24-33.33%MissN/A40 up, 0 downMay 13, 2024$566000
    Dec 31, 2023-$0.21-$0.29-$0.44 - -$0.26+27.59%BeatN/A60 up, 0 downMar 6, 2024$7.21M
    Sep 30, 2023-$0.24-$0.44-$0.54 - -$0.25+45.45%BeatN/A50 up, 0 downNov 9, 2023$3.89M
    Jun 30, 2023-$0.51-$0.78-$1.04 - -$0.27+34.62%BeatN/A41 up, 0 downAug 10, 2023$3.15M
    Mar 31, 2023-$0.93-$0.75-$0.80 - -$0.69-24.00%MissN/A40 up, 0 downMay 10, 2023$6.80M
    Dec 31, 2022-$0.78-$0.70-$0.80 - -$0.63-11.43%MissN/A40 up, 0 downMar 8, 2023$3.10M
    Sep 30, 2022-$0.67-$0.71-$0.80 - -$0.65+5.63%BeatN/A40 up, 0 downNov 9, 2022$3.36M
    Jun 30, 2022-$0.63-$0.72N/A+12.50%BeatN/AN/A0 up, 0 downAug 10, 2022$4.06M
    Mar 31, 2022-$0.67-$0.62-$0.90 - -$0.57-8.06%MissN/A40 up, 0 downMay 9, 2022$3.02M
    Dec 31, 2021-$0.38-$0.73-$0.86 - -$0.60+47.95%BeatN/A5N/AMar 9, 2022$2.85M
    Sep 30, 2021-$0.80-$0.48-$0.96 - -$0.37-66.67%MissN/A21 up, 0 downNov 10, 2021$2.41M
    Jun 30, 2021-$7.69-$4.09N/A-88.02%MissN/AN/AN/AJul 15, 2021$2.85M
    Mar 31, 2021-$1.11-$6.40N/A+82.66%BeatN/AN/AN/AApr 30, 2021$2.03M
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.00, after -$1.15 the year before. It was -$9.98 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.00N/A
    Dec 31, 2024-$1.15N/A
    Dec 31, 2023-$1.89N/A
    Dec 31, 2022-$2.75N/A
    Dec 31, 2021-$9.98N/A

    Frequently Asked Questions About TCRX

    When is Tscan Therapeutics's next earnings date?

    Tscan Therapeutics's next earnings report is expected for Mar 2, 2027.

    Did TCRX beat earnings estimates last quarter?

    No. Tscan Therapeutics reported EPS of -$0.25 for the quarter ended Sep 30, 2026, below the -$0.18 estimate by 38.89%.

    What EPS do analysts expect from TCRX next quarter?

    The consensus EPS estimate for Tscan Therapeutics for the quarter ending Dec 31, 2026 is -$0.17 from 6 analysts, with estimates from -$0.21 to -$0.09.

    How often does TCRX beat earnings estimates?

    Tscan Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.03%.